Stefan K. Barta on Muck Rack

Stefan K. Barta

As seen in: Color Research & Application, Nature, Wiley Online Library, MDPI, HemOnc Today, Chinese Clinical Oncology, Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stefan K.

Contact Stefan K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Naïve CD4 + T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

|
By Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael Cook, Nasheed M. Hossain, Colin Thomas , Vitor De Souza, Mohannad H Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Alberto Carturan, Patrizia Porazzi, Joseph A Fraietta, Stephen J. Schuster, Ivan Maillard, Marco Ruella, Daniel J. Landsburg, Vrutti Patel, Antonio Imparato
| Nature
Open in Who Shared Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar , Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover , Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

|
By Brian L. Egleston, Raphael Steiner, Ariela Noy, Verónica Alzate Carvajal, Emeline R. Chong, Seda S. Tolu, Gaston Jean-Louis, Jennifer E Amengual, Romil Patel, Sairah Ahmed, John Sharp , Timothy Voorhees, Robert A Baiocchi, Andres Ramirez-Gamero, Jorge Castillo , Emily R. Hamburger, Imran Nizamuddin, Neha Mehta-Shah, Jose D. Sandoval-Sus, Alexandra E. Rojek, Peter A. Riedell, Niloufer Khan, Alexey B. Danilov, Paul Rubinstein, Anthony Ariotti, Gita Suneja, Charles J Milrod, Adam Olszewski, Gordon J. Smilnak, Emily Ayers, Sahaj Desai, Joanna Rhodes, Gabriella Magarelli, Tatyana Feldman, Meredith Pellon, David M. Aboulafia, William Bae, Carlos Galvez, Mehdi Hamadani, Stefan K. Barta, Matthew Hamby, Zachary A. K. Frosch, Christopher Dittus, Vinod Solipuram, Alexander Vartanov, Vineel Bhatlapenumarthi
| Nature
Abstract Plasmablastic lymphoma (PBL) is a rare, aggressive AIDS-related lymphoma observed in patients with immunosuppressed states as well as in immunocompetent individuals. We sought to determine survival outcomes, prognostic factors, and optimal treatment regimens in a large, contemporary cohort of patients with PBL in the United States. We performed a multicenter, retrospective cohort study, including 344 patients diagnosed with PBL between 2005 and 2022.
Open in Who Shared Issue with article?
See all 17 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Stefan K.

Contact Stefan K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified